Piotroski F-Score of 2 is low, which usually implies poor business operation.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Jacobio Pharmaceuticals Group Co has an F-score of 2. It is a bad or low score, which usually implies poor business operation.
The historical rank and industry rank for Jacobio Pharmaceuticals Group Co's Piotroski F-Score or its related term are showing as below:
JBPHF'
s Piotroski F-Score Range Over the Past 10 Years
Min: 2 Med: 3 Max: 7
Current: 2
During the past 8 years, the highest Piotroski F-Score of Jacobio Pharmaceuticals Group Co was 7. The lowest was 2. And the median was 3.
Jacobio Pharmaceuticals Group Co (OTCPK:JBPHF) Piotroski F-Score Explanation
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Jacobio Pharmaceuticals Group Co Piotroski F-Score Related Terms
Jacobio Pharmaceuticals Group Co Piotroski F-Score Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jacobio Pharmaceuticals Group Co Piotroski F-Score Chart
JBPHF vs VRTX, REGN, ALNY: Piotroski F-Score Comparison
For the Biotechnology subindustry, Jacobio Pharmaceuticals Group Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jacobio Pharmaceuticals Group Co Piotroski F-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jacobio Pharmaceuticals Group Co's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Jacobio Pharmaceuticals Group Co's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Jacobio Pharmaceuticals Group Co's current Net Income (TTM) was -20.73.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Jacobio Pharmaceuticals Group Co's current Cash Flow from Operations (TTM) was -29.96.
==> Negative ==> Score 0.
Question 3. Change in Return on Assets
Compare this year's return on assets (1) to last year's return on assets.
Jacobio Pharmaceuticals Group Co's return on assets of this year was -0.11102897. Jacobio Pharmaceuticals Group Co's return on assets of last year was -0.10455992.
==> Last year is higher ==> Score 0.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Jacobio Pharmaceuticals Group Co's gearing of this year was 0.11434073. Jacobio Pharmaceuticals Group Co's gearing of last year was 0.06047175.
==> Last year is lower than this year ==> Score 0.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Jacobio Pharmaceuticals Group Co's current ratio of this year was 5.09866476. Jacobio Pharmaceuticals Group Co's current ratio of last year was 4.8944686.
==> This year's current ratio is higher. ==> Score 1.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Jacobio Pharmaceuticals Group Co's number of shares in issue this year was 774.511. Jacobio Pharmaceuticals Group Co's number of shares in issue last year was 774.809.
==> There is smaller number of shares in issue this year, or the same. ==> Score 1.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Jacobio Pharmaceuticals Group Co's gross margin of this year was 0.98881579. Jacobio Pharmaceuticals Group Co's gross margin of last year was 1.
==> Last year's gross margin is higher ==> Score 0.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Jacobio Pharmaceuticals Group Co's asset turnover of this year was 0.04071116. Jacobio Pharmaceuticals Group Co's asset turnover of last year was 0.10455503.
==> Last year's asset turnover is higher ==> Score 0.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
0
+
0
+
0
+
0
+
0
+
1
+
1
+
0
+
0
=
2
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Jacobio Pharmaceuticals Group Co has an F-score of 2. It is a bad or low score, which usually implies poor business operation.
Jacobio Pharmaceuticals Group Co (JBPHF) has a Piotroski F-Score of 2 as of Jun. 27, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Jacobio Pharmaceuticals Group Co and its competitors. This is 33% below median its historical median of 3.00. Over the past decade, Jacobio Pharmaceuticals Group Co's Piotroski F-Score has ranged from 2.00 to 7.00. According to the industry distribution chart, Jacobio Pharmaceuticals Group Co ranks #981 out of 1342 companies in the Biotechnology industry, placing it in the top 73.1%.
Is Jacobio Pharmaceuticals Group Co's Piotroski F-Score too high?
Jacobio Pharmaceuticals Group Co's current Piotroski F-Score of 2 is 33% below median its 10-year median of 3.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 7.00. The Biotechnology industry median Piotroski F-Score is 3.00. Jacobio Pharmaceuticals Group Co's value of 2 is 33.3% below this industry median. Based on the distribution chart, Jacobio Pharmaceuticals Group Co ranks #981 out of 1342 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Jacobio Pharmaceuticals Group Co has a GF Score™ of 54/100, reflecting its overall financial health beyond just this single metric.
How does Jacobio Pharmaceuticals Group Co's Piotroski F-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Jacobio Pharmaceuticals Group Co ranks #981 out of 1342 companies for Piotroski F-Score. This places Jacobio Pharmaceuticals Group Co in the lower half of its industry. The industry median Piotroski F-Score is 3.00. Jacobio Pharmaceuticals Group Co's value of 2 is 33.3% below this benchmark. Historically, Jacobio Pharmaceuticals Group Co's own Piotroski F-Score has ranged from 2.00 to 7.00 over the past decade. While the company's 10-year median is 3.00 vs. the industry median of 3.00, Jacobio Pharmaceuticals Group Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,342 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jacobio Pharmaceuticals Group Co's current Piotroski F-Score of 2 is 33.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Jacobio Pharmaceuticals Group Co and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jacobio Pharmaceuticals Group Co's current Piotroski F-Score is 2, which is 33% below median its own 10-year median of 3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jacobio Pharmaceuticals Group Co stock overvalued right now?
Jacobio Pharmaceuticals Group Co (JBPHF) has a current Piotroski F-Score of 2. The stock's GF Value™ is $0.42, compared to a current price of $0.87 — trading 106.6% above its estimated fair value. The current Piotroski F-Score is 2, which is 33% below median its 10-year median of 3.00 and 33.3% below the Biotechnology industry median of 3.00. Jacobio Pharmaceuticals Group Co's overall GF Score™ is 54/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Jacobio Pharmaceuticals Group Co (JBPHF), the current Piotroski F-Score is 2 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jacobio Pharmaceuticals Group Co (JBPHF) Overvalued in 2026?
Based on GuruFocus' analysis, Jacobio Pharmaceuticals Group Co stock appears to be overvalued.
The current stock price of $0.87 is trading 106.6% above its estimated GF Value™ of $0.42.
Key valuation signals for JBPHF:
Piotroski F-Score: 2 (33% below median its 10-year median of 3.00)
GF Value™: $0.42 vs. price of $0.87 (106.6% above fair value)
Industry Position: 33.3% below the Biotechnology median (#981 of 1342)
No single metric tells the full story. See the JBPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jacobio Pharmaceuticals Group Co Business Description
Jacobio Pharmaceuticals Group Co Ltd is a clinical-stage pharmaceutical company focusing on the in-house discovery and development of oncology therapies. The company is engaged in developing breakthrough cancer therapies for patients. The producst pipeline of the company includes KRAS G12C inhibitor, SHP2 inhibitor, Pan-KRAS inhibitor, KRAS G12D ADC JAB-BX600, Aurora Kinase A (AURKA) inhibitor, BET inhibitor, P53 Y220C mutant proteins, and others.
54GF Score
Get the complete analysis for JBPHF
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JBPHF has been successfully added to your 
